Proportional Feedback Control of Energy Intake During Obesity Pharmacotherapy
Authors:
Open Access
- 25 October 2017
- Vol. 25 (12) , 2088-2091
Abstract
Objective: Obesity pharmacotherapies result in an exponential time course for energy intake whereby large early decreases dissipate over time. This pattern of declining drug efficacy to decrease energy intake results in a weight loss plateau within approximately 1 year. This study aimed to elucidate the physiology underlying the exponential decay of drug effects on energy intake.Methods: Placebo‐subtracted energy intake time courses were examined during long‐term obesity pharmacotherapy trials for 14 different drugs or drug combinations within the theoretical framework of a proportional feedback control system regulating human body weight.Results: Assuming each obesity drug had a relatively constant effect on average energy intake and did not affect other model parameters, our model correctly predicted that long‐term placebo‐subtracted energy intake was linearly related to early reductions in energy intake according to a prespecified equation with no free parameters. The simple model explained about 70% of the variance between drug studies with respect to the long‐term effects on energy intake, although a significant proportional bias was evident.Conclusions: The exponential decay over time of obesity pharmacotherapies to suppress energy intake can be interpreted as a relatively constant effect of each drug superimposed on a physiological feedback control system regulating body weight.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (1-ZIA-DK013036-09)
This publication has 22 references indexed in Scilit:
- Modeling Metabolic Adaptations and Energy Regulation in HumansAnnual Review of Nutrition, 2012
- Controlled‐Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)Obesity, 2012
- Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension studyThe American Journal of Clinical Nutrition, 2012
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutideInternational Journal of Obesity, 2011
- Quantification of the effect of energy imbalance on bodyweightThe Lancet, 2011
- Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese SubjectsNew England Journal of Medicine, 2010
- Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight ManagementNew England Journal of Medicine, 2010
- Medications for Weight ReductionEndocrinology and Metabolism Clinics of North America, 2008
- Pharmacotherapy for ObesityDrugs, 2005
- Orlistat in the Long-term Treatment of Obesity in Primary Care SettingsArchives of Family Medicine, 2000